Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH): A Patient Guide

Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is an ultra-rare genetic disorder that fundamentally changes how the body handles two essential minerals: phosphate and calcium. At its core, HHRH is caused by a defect in the kidneys’ proximal renal tubule—the part of the kidney responsible for reabsorbing nutrients—usually due to mutations in the SLC34A3 gene. Because the kidneys cannot properly reclaim phosphate from the urine, the blood levels of this mineral drop, depriving the bones of the minerals they need to grow and stay strong. This leads to rickets—characterized by bone softening, bowing of the legs, and growth delays—which often serves as the first visible sign of the condition in children, or osteomalacia in adults ^[1][2].

What makes HHRH unique among bone diseases is its specific biological paradox involving vitamin D. In many other forms of rickets, the body lacks enough vitamin D or produces a hormone called FGF23 that suppresses it. In HHRH, however, the process is FGF23-independent. The body reacts to low phosphate by overproducing its own active vitamin D (1,25-dihydroxyvitamin D), which in turn causes the gut to absorb excessive amounts of calcium. This extra calcium is then excreted into the urine—a state known as hypercalciuria. This creates a dual-system challenge where the bones are starved of minerals while the kidneys must process high levels of calcium, leading to an increased risk of kidney stones and calcium deposits in the kidney tissue (nephrocalcinosis) ^[1][3].

Because of this unique biology, the standard of care for HHRH is distinct. Unlike more common types of hereditary rickets, HHRH is managed primarily with oral phosphate supplements as the first-line treatment. A critical rule of treatment is the strict avoidance of prescribed active vitamin D analogs (such as calcitriol or alfacalcidol), as adding more active hormone to a system that is already overproducing it can worsen kidney calcification. However, ordinary nutritional vitamin D (like cholecalciferol) may still be needed if a patient has a standard deficiency, which should be guided by a doctor.

Navigating this “bone-kidney” balance requires a dedicated multidisciplinary team, typically led by both endocrinologists and nephrologists, who monitor blood and urine chemistry to ensure the bones are healing while minimizing kidney risk ^[4][5].

Living with HHRH is a lifelong journey of careful, individualized monitoring and advocacy. Early, individualized treatment can significantly improve bone findings, while kidney risk varies between patients. By focusing on consistent phosphate replacement, vigilant kidney screening, and lifestyle measures like adequate hydration and maintaining a normal, age-appropriate dietary calcium intake, it is possible to manage the symptoms of HHRH and support long-term well-being ^[6][7].